Agonist replacement therapy for cocaine dependence: a translational review - PubMed (original) (raw)

Review

Agonist replacement therapy for cocaine dependence: a translational review

Craig R Rush et al. Future Med Chem. 2012 Feb.

Abstract

Cocaine use disorders are prevalent throughout the world. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. This paper reviews the translational literature, including preclinical experiments, human laboratory studies and clinical trials, to determine whether agonist-replacement therapy is a viable strategy for managing cocaine dependence. Discussion is limited to transporter blockers (i.e., methylphenidate) and releasers (i.e., amphetamine analogs) that are available for use in humans in the hope of impacting clinical research and practice more quickly. The translational review suggests that agonist-replacement therapy, especially monoamine releasers, may be effective for managing cocaine dependence. Future directions for medications development are also discussed because the viability of agonist-replacement therapy for cocaine dependence may hinge on identifying novel compounds or formulations that have less abuse and diversion potential.

PubMed Disclaimer

Similar articles

• Agonist replacement for stimulant dependence: a review of clinical research.
  Stoops WW, Rush CR. Stoops WW, et al. Curr Pharm Des. 2013;19(40):7026-35. doi: 10.2174/138161281940131209142843. Curr Pharm Des. 2013. PMID: 23574440 Free PMC article. Review.
• Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
  Rush CR, Stoops WW, Hays LR. Rush CR, et al. Drug Alcohol Depend. 2009 Jan 1;99(1-3):261-71. doi: 10.1016/j.drugalcdep.2008.08.009. Epub 2008 Oct 15. Drug Alcohol Depend. 2009. PMID: 18926645 Free PMC article. Clinical Trial.
• Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
  Jordan CJ, Cao J, Newman AH, Xi ZX. Jordan CJ, et al. Neuropharmacology. 2019 Nov 1;158:107609. doi: 10.1016/j.neuropharm.2019.04.015. Epub 2019 Apr 19. Neuropharmacology. 2019. PMID: 31009632 Free PMC article. Review.
• Psychostimulant treatment of cocaine dependence.
  Mariani JJ, Levin FR. Mariani JJ, et al. Psychiatr Clin North Am. 2012 Jun;35(2):425-39. doi: 10.1016/j.psc.2012.03.012. Epub 2012 Apr 26. Psychiatr Clin North Am. 2012. PMID: 22640764 Free PMC article. Review.

Cited by

• Safety and tolerability of intranasal cocaine during phendimetrazine maintenance.
  Stoops WW, Strickland JC, Hays LR, Rayapati AO, Lile JA, Rush CR. Stoops WW, et al. Psychopharmacology (Berl). 2016 Jun;233(11):2055-2063. doi: 10.1007/s00213-016-4260-7. Epub 2016 Mar 1. Psychopharmacology (Berl). 2016. PMID: 26932737 Free PMC article.
• Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans.
  Lile JA, Stoops WW, Rush CR, Negus SS, Glaser PE, Hatton KW, Hays LR. Lile JA, et al. Drug Alcohol Depend. 2016 Aug 1;165:111-9. doi: 10.1016/j.drugalcdep.2016.05.022. Epub 2016 May 28. Drug Alcohol Depend. 2016. PMID: 27269368 Free PMC article. Clinical Trial.
• Influence of Prolonged Serotonin and Ergovaline Pre-Exposure on Vasoconstriction Ex Vivo.
  Valente EEL, Harmon DL, Klotz JL. Valente EEL, et al. Toxins (Basel). 2021 Dec 23;14(1):9. doi: 10.3390/toxins14010009. Toxins (Basel). 2021. PMID: 35050986 Free PMC article.
• The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.
  Karkhanis AN, Beveridge TJ, Blough BE, Jones SR, Ferris MJ. Karkhanis AN, et al. Drug Alcohol Depend. 2016 Sep 1;166:51-60. doi: 10.1016/j.drugalcdep.2016.06.020. Epub 2016 Jun 25. Drug Alcohol Depend. 2016. PMID: 27394931 Free PMC article.
• Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users.
  Levin FR, Mariani JJ, Pavlicova M, Choi CJ, Mahony AL, Brooks DJ, Bisaga A, Dakwar E, Carpenter KM, Naqvi N, Nunes EV, Kampman K. Levin FR, et al. Drug Alcohol Depend. 2020 Jan 1;206:107700. doi: 10.1016/j.drugalcdep.2019.107700. Epub 2019 Nov 1. Drug Alcohol Depend. 2020. PMID: 31753736 Free PMC article. Clinical Trial.

References

1. 1. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD, USA: Office of Applied Studies; 2009.
2. 1. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) Highlights – 2007 National Admissions to Substance Abuse Treatment Services. Rockville, MD, USA: Office of Applied Studies; 2007.
3. 1. European Monitoring Centre for Drugs and Drug Addiction. 2009 Annual report on the state of the drugs problem in Europe. Luxembourg: Publications Office of the European Union; 2009.
4. 1. Chen K, Scheier LM, Kandel DB. Effects of chronic cocaine use on physical health: a prospective study in a general population sample. Drug Alcohol Depend. 1996;43:23–37. - PubMed
5. 1. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation. 2010;122:2558–2569. - PubMed

Publication types

MeSH terms

Grants and funding

• R01 DA021155-04/DA/NIDA NIH HHS/United States
• DA021155/DA/NIDA NIH HHS/United States
• R01 DA025032-05/DA/NIDA NIH HHS/United States
• R01 DA021155/DA/NIDA NIH HHS/United States
• R21 DA024089/DA/NIDA NIH HHS/United States
• DA024089/DA/NIDA NIH HHS/United States
• DA025032/DA/NIDA NIH HHS/United States
• R01 DA025032/DA/NIDA NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Medical

  • MedlinePlus Health Information